London · Delayed Price · Currency is GBP · Price in GBX Poolbeg Pharma Earnings Call Transcripts
Fiscal Year 2026
-
POLB 001's interim TOPICAL trial results show strong safety in multiple myeloma patients, with the Safety Review Committee endorsing continued study and no protocol changes. The program is attracting significant commercial and partnering interest, supported by robust payer research and a clear regulatory path.
Fiscal Year 2025
-
POLB 001 is advancing toward a key clinical data readout in CRS prevention, supported by strong financials, strategic partnerships, and a robust patent portfolio. The company is also preparing to launch an oral GLP-1 trial for obesity, targeting large and growing markets.
-
POLB 001 is advancing to a phase IIa trial as a first-in-class oral prophylactic for cancer immunotherapy-induced CRS, with strong preclinical and phase 1 data, FDA orphan drug status, and rapid proof-of-concept data expected in 2024. The program targets a multibillion-dollar market and aims to expand immunotherapy access.
-
POLB001 has received FDA orphan drug designation, unlocking regulatory incentives and exclusivity. A phase 2A trial in multiple myeloma patients will start in H2 2025, with interim data in H1 2026. The program targets a $10B+ market, with strong pharma interest and a robust cash runway.